Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409240 | 0.85 | L3MBTL1 (0.57) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4007129 | 0.82 | L3MBTL1 (0.53) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4924387 | 0.80 | CYP1A2 (0.60) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3404706 | 0.80 | HDAC6 (0.55) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4648730 | 0.80 | HDAC6 (0.58) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL12017926 | 0.80 | EGLN1 (0.45) | EGLN1 | |
| SCHEMBL3407381 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL20641182 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL8288231 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL3412142 | 0.79 | HDAC6 (0.60) | NPC1RAB9ASMN1; SMN2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | NPC1 603/4885RAB9A 1135/4885SMN1; SMN2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.